Merck Group
·
Contact
·
Deutsche Version
·
Sitemap
·
Help
·
Imprint
Report Home
Sitemap
Merck 2007 at a glance
Achievements of 2007
Development 2003-2007
Business sectors
Financial calendar
Letter from Karl-Ludwig Kley
Corporate governance and bodies
Corporate governance
Merck KGaA
Compensation and ownership of shares
Report of the Supervisory Board
Executive Board
Karl-Ludwig Kley
Michael Becker
Bernd Reckmann
Elmar Schnee
Walter W. Zywottek
Supervisory Board
Board of Partners of E. Merck OHG
Merck shares
Share price development and influencing factors
Share data
Shareholder structure
Information on capital and shares
Management Report
Sales development
Business sectors
Regions
Financial position and results of operations
Operating result
Earnings contributions
Financial result
Profit after tax
Dividend proposal
Free cash flow
Research and development
Capital spending
Total assets
Net debt
Value added
Responsibility
Employees
Social Charter
Community
Environment
Risk report
Business-related risks
Financial risks
Accounting risks
Legal risks
Other risks
Report on expected developments
Merck
Pharmaceuticals
Chemicals
Subsequent events
Management Report: Divisions
In focus
Effective therapies
Strong presence in the US
Debut in Japan
Leadership in LCD
Detecting bacteria
A sunny future
Merck Serono
Business development
Regions
Therapeutic areas
Markets
Oncology
Neurodegenerative Diseases
Fertility
Endocrinology
CardioMetabolic Care
Dermatology
Research and development
Overview compounds
Oncology
Neurodegenerative Diseases
Fertility
Autoimmune and inflammatory diseases
Endocrinology
Consumer Health Care
Business development
Regions
Brands
Liquid Crystals
Business development
Research and development
Trend toward LCD TVs
Performance & Life Science Chemicals Profile
Business development
Regions
Laboratory Business
Profile
Business development
Life Science Solutions
Profile
Business development
Pigments
Profile
Business development
Corporate and Other
Generics
Financial Statements
Income Statement
Balance Sheet
Segment Reporting
Business sectors
Regions
Cash Flow Statement
Free Cashflow
Income and Expense
Changes in Net Equity
Notes
Reporting structure
Acquisitions
Disposals/Discontinued operations
Accounting policies
Notes to the income statement
Sales
Royalty income
Cost of sales
Marketing and selling expenses
Administration expenses
Other operating income and expenses
Research and development
Amortization of intangible assets
Investment result
Exceptional items
Financial result
Income tax
Profit after tax from discontinued operations
Minority interest
Earnings per share
Notes to the balance sheet
Cash and cash equivalents
Marketable securities
Trade accounts receivable
Inventories
Other assets
Tax receivables
Assets/ liabilities held for sale
Intangible assets
Property, plant and equipment
Non-current financial assets
Financial liabilities
Trade accounts payable
Other liabilities
Tax liabilities
Provisions
Provisions for pensions
Net equity
Notes to the segment reporting
Notes to the cash flow statement
Net cash flows from operating activities
Net cash flows from investing activities
Net cash flows from financing activities
Cash and cash equivalents
Free cash flow
Other disclosures
Derivative financial instruments
Management of financial risks
Other disclosures on financial instruments
Contingent liabilities
Other financial obligations
Personnel expenses
Material costs
Auditors' fees
Corporate Governance
Companies opting for exemption
Related-party disclosures
Auditor's Report
Search this report
Services
Print page
Recommend page
Downloads
Order online
Merck 2007 at a glance
Letter from Karl-Ludwig Kley
Corporate governance
and bodies
Merck shares
Management Report
Management Report: Divisions
Financial Statements
Notes
made by GeBer Geschäftsberichte - a passion to report - Online Annual Report
